{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:19:42Z","timestamp":1790785182311,"version":"4.1.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-85832-3","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T17:42:23Z","timestamp":1738950143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness of antipsychotic medication in patients with schizophrenia in a real world retrospective observational study in Ethiopia"],"prefix":"10.1038","volume":"15","author":[{"given":"Mulualem","family":"Kelebie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Getasew","family":"Kibralew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gebresilassie","family":"Tadesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gidey","family":"Rtbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mekidem","family":"aderaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wondale","family":"Endeshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitiku","family":"Belachew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulu","family":"Muche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diemesew","family":"Getnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setegn","family":"Fentahun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"issue":"1","key":"85832_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.22270\/jddt.v10i1.3865","volume":"10","author":"R Bangwal","year":"2020","unstructured":"Bangwal, R. et al. Psychotic disorders, definition, sign and symptoms, antipsychotic drugs, mechanism of action, pharmacokinetics & pharmacodynamics with side effects & adverse drug reactions: updated systematic review article. J. Drug Del. Ther. 10 (1), 163\u2013172 (2020).","journal-title":"J. Drug Del. Ther."},{"key":"85832_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ajp.2014.08.002","volume":"11","author":"D Bruijnzeel","year":"2014","unstructured":"Bruijnzeel, D., Suryadevara, U. & Tandon, R. Antipsychotic treatment of schizophrenia: An update. Asian J. Psychiatry 11, 3\u20137 (2014).","journal-title":"Asian J. Psychiatry"},{"issue":"1","key":"85832_CR3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4088\/JCP.7085tx2cj","volume":"72","author":"R Tandon","year":"2011","unstructured":"Tandon, R. Antipsychotics in the treatment of schizophrenia: An overview. J. Clin. Psychiatry Suppl. 72 (1), 4 (2011).","journal-title":"J. Clin. Psychiatry Suppl."},{"issue":"1","key":"85832_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41537-020-00122-3","volume":"6","author":"S Oh","year":"2020","unstructured":"Oh, S. et al. Effectiveness of antipsychotic drugs in schizophrenia: A 10-year retrospective study in a Korean tertiary hospital. Npj Schizophrenia 6 (1), 32 (2020).","journal-title":"Npj Schizophrenia"},{"issue":"12","key":"85832_CR5","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman, J. A. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (12), 1209\u20131223 (2005).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"85832_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2174\/0929867043456043","volume":"11","author":"A Serretti","year":"2004","unstructured":"Serretti, A. et al. New antipsychotics and schizophrenia: A review on efficacy and side effects. Curr. Med. Chem. 11 (3), 343\u2013358 (2004).","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"85832_CR7","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.mehy.2012.11.042","volume":"80","author":"AM Isom","year":"2013","unstructured":"Isom, A. M. et al. Antipsychotic medications, glutamate, and cell death: A hidden, but common medication side effect? Med. Hypotheses 80 (3), 252\u2013258 (2013).","journal-title":"Med. Hypotheses"},{"key":"85832_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2165\/00023210-200923030-00002","volume":"23","author":"P Thomas","year":"2009","unstructured":"Thomas, P. et al. Management of patients presenting with acute psychotic episodes of schizophrenia. CNS Drugs 23, 193\u2013212 (2009).","journal-title":"CNS Drugs"},{"issue":"1","key":"85832_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.mp.4001556","volume":"10","author":"S Miyamoto","year":"2005","unstructured":"Miyamoto, S. et al. Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10 (1), 79\u2013104 (2005).","journal-title":"Mol. Psychiatry"},{"key":"85832_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","volume":"20","author":"J Horacek","year":"2006","unstructured":"Horacek, J. et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20, 389\u2013409 (2006).","journal-title":"CNS Drugs"},{"issue":"1","key":"85832_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/bmb\/ldv017","volume":"114","author":"J Lally","year":"2015","unstructured":"Lally, J. & MacCabe, J. H. Antipsychotic medication in schizophrenia: A review. Br. Med. Bull. 114 (1), 169\u2013179 (2015).","journal-title":"Br. Med. Bull."},{"issue":"1","key":"85832_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1192\/bjp.bp.109.070961","volume":"197","author":"A Pope","year":"2010","unstructured":"Pope, A. et al. Assessment of adverse effects in clinical studies of antipsychotic medication: Survey of methods used. Br. J. Psychiatry 197 (1), 67\u201372 (2010).","journal-title":"Br. J. Psychiatry"},{"issue":"11","key":"85832_CR13","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1016\/S0149-2918(00)89080-3","volume":"23","author":"J Mullen","year":"2001","unstructured":"Mullen, J. et al. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin. Ther. 23 (11), 1839\u20131854 (2001).","journal-title":"Clin. Ther."},{"issue":"4","key":"85832_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1192\/bjp.bp.110.083907","volume":"199","author":"T Suzuki","year":"2011","unstructured":"Suzuki, T. et al. Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia. Br. J. Psychiatry 199 (4), 275\u2013280 (2011).","journal-title":"Br. J. Psychiatry"},{"issue":"7","key":"85832_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1176\/appi.ajp.2015.14101329","volume":"172","author":"MT Samara","year":"2015","unstructured":"Samara, M. T. et al. Early improvement as a predictor of later response to antipsychotics in schizophrenia: A diagnostic test review. Am. J. Psychiatry 172 (7), 617\u2013629 (2015).","journal-title":"Am. J. Psychiatry"},{"key":"85832_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.schres.2019.04.022","volume":"209","author":"R Schennach","year":"2019","unstructured":"Schennach, R. et al. Remission in schizophrenia\u2014what are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression. Schizophr. Res. 209, 185\u2013192 (2019).","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"85832_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.schres.2010.10.024","volume":"126","author":"P Masand","year":"2011","unstructured":"Masand, P., O\u2019Gorman, C. & Mandel, F. S. Clinical global impression of improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: Analyses of ziprasidone clinical study data. Schizophr. Res. 126 (1\u20133), 174\u2013183 (2011).","journal-title":"Schizophr. Res."},{"issue":"10","key":"85832_CR18","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1038\/sj.npp.1301147","volume":"31","author":"S Leucht","year":"2006","unstructured":"Leucht, S. et al. Linking the PANSS, BPRS, and CGI: Clinical implications. Neuropsychopharmacology 31 (10), 2318\u20132325 (2006).","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"85832_CR19","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/archgenpsychiatry.2012.847","volume":"69","author":"MO Nielsen","year":"2012","unstructured":"Nielsen, M. O. et al. Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia. Arch. Gen. Psychiatry 69 (12), 1195\u20131204 (2012).","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"85832_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/acps.12849","volume":"137","author":"CH Lin","year":"2018","unstructured":"Lin, C. H. et al. Early improvement in PANSS-30, PANSS\u20108, and PANSS\u20106 scores predicts ultimate response and remission during acute treatment of schizophrenia. Acta Psychiatry. Scand. 137 (2), 98\u2013108 (2018).","journal-title":"Acta Psychiatry. Scand."},{"issue":"3","key":"85832_CR21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","volume":"162","author":"NC Andreasen","year":"2005","unstructured":"Andreasen, N. C. et al. Remission in schizophrenia: Proposed criteria and rationale for consensus. Am. J. Psychiatry 162 (3), 441\u2013449 (2005).","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"85832_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41537-019-0091-y","volume":"6","author":"L Phahladira","year":"2020","unstructured":"Phahladira, L. et al. Early recovery in the first 24 months of treatment in first-episode schizophrenia-spectrum disorders. NPJ Schizophrenia 6 (1), 2 (2020).","journal-title":"NPJ Schizophrenia"},{"key":"85832_CR23","first-page":"364","volume":"18","author":"AEA Ya\u011fcio\u011flu","year":"2007","unstructured":"Ya\u011fcio\u011flu, A. E. A. The mechanisms of action of antipsychotic drugs: Is atypicality superior in schizophrenia treatment? Turk. Psikiyatri Derg 18, 364\u2013374 (2007).","journal-title":"Turk. Psikiyatri Derg"},{"key":"85832_CR24","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.2165\/0003495-200868160-00002","volume":"68","author":"D Bishara","year":"2008","unstructured":"Bishara, D. & Taylor, D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 68, 2269\u20132292 (2008).","journal-title":"Drugs"},{"issue":"1","key":"85832_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/18387357.2015.1080651","volume":"14","author":"P Morrison","year":"2016","unstructured":"Morrison, P., Meehan, T. & Stomski, N. Australian mental health staff response to antipsychotic medication side effects: The perceptions of consumers. Adv. Mental Health 14 (1), 4\u201313 (2016).","journal-title":"Adv. Mental Health"},{"issue":"3\u20134","key":"85832_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0022-3956(98)00023-5","volume":"32","author":"MD Jibson","year":"1998","unstructured":"Jibson, M. D. & Tandon, R. New atypical antipsychotic medications. J. Psychiatr. Res. 32 (3\u20134), 215\u2013228 (1998).","journal-title":"J. Psychiatr. Res."},{"issue":"20","key":"85832_CR27","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1001\/jama.290.20.2693","volume":"290","author":"R Rosenheck","year":"2003","unstructured":"Rosenheck, R. et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: A randomized controlled trial. Jama 290 (20), 2693\u20132702 (2003).","journal-title":"Jama"},{"issue":"4","key":"85832_CR28","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1176\/ajp.154.4.466","volume":"154","author":"GD Tollefson","year":"1997","unstructured":"Tollefson, G. D. & Sanger, T. M. Negative symptoms: A path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. Am. J. Psychiatry 154 (4), 466\u2013474 (1997).","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"85832_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1056\/NEJMoa002028","volume":"346","author":"JG Csernansky","year":"2002","unstructured":"Csernansky, J. G., Mahmoud, R. & Brenner, R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 346 (1), 16\u201322 (2002).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"85832_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2005.07.038","volume":"81","author":"RS Keefe","year":"2006","unstructured":"Keefe, R. S. et al. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr. Res. 81 (1), 1\u201315 (2006).","journal-title":"Schizophr. Res."},{"key":"85832_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12991-019-0254-2","volume":"19","author":"R Tandon","year":"2020","unstructured":"Tandon, R. et al. The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: A worldwide, cross-sectional, web-based survey. Ann. Gen. Psychiatry 19, 1\u201311 (2020).","journal-title":"Ann. Gen. Psychiatry"},{"issue":"5","key":"85832_CR32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1177\/0004867415608244","volume":"50","author":"NJ Stomski","year":"2016","unstructured":"Stomski, N. J., Morrison, P. & Meyer, A. Antipsychotic medication side effect assessment tools: A systematic review. Australian New. Z. J. Psychiatry 50 (5), 399\u2013409 (2016).","journal-title":"Australian New. Z. J. Psychiatry"},{"issue":"1\u20132","key":"85832_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0920-9964(01)00271-7","volume":"56","author":"DA Wirshing","year":"2002","unstructured":"Wirshing, D. A. et al. Sexual side effects of novel antipsychotic medications. Schizophr. Res. 56 (1\u20132), 25\u201330 (2002).","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"85832_CR34","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.schres.2009.03.026","volume":"112","author":"HA Wolters","year":"2009","unstructured":"Wolters, H. A. et al. Effects and side effects of antipsychotic treatment in schizophrenia: Pros and cons of available self-rating scales. Schizophr. Res. 112 (1\u20133), 114\u2013118 (2009).","journal-title":"Schizophr. Res."},{"issue":"5","key":"85832_CR35","doi-asserted-by":"publisher","first-page":"74","DOI":"10.5498\/wjp.v2.i5.74","volume":"2","author":"FJ Acosta","year":"2012","unstructured":"Acosta, F. J. et al. Medication adherence in schizophrenia. World J. Psychiatry 2 (5), 74 (2012).","journal-title":"World J. Psychiatry"},{"issue":"4","key":"85832_CR36","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/2045125312474019","volume":"3","author":"K Higashi","year":"2013","unstructured":"Higashi, K. et al. Medication adherence in schizophrenia: Factors influencing adherence and consequences of nonadherence, a systematic literature review. Therapeutic Adv. Psychopharmacol. 3 (4), 200\u2013218 (2013).","journal-title":"Therapeutic Adv. Psychopharmacol."},{"issue":"2","key":"85832_CR37","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/0091217416636601","volume":"51","author":"SV Phan","year":"2016","unstructured":"Phan, S. V. Medication adherence in patients with schizophrenia. Int. J. Psychiatry Med. 51 (2), 211\u2013219 (2016).","journal-title":"Int. J. Psychiatry Med."},{"key":"85832_CR38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4088\/JCP.v67n1120","volume":"67","author":"S Leucht","year":"2006","unstructured":"Leucht, S. & Heres, S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J. Clin. Psychiatry 67, 3 (2006).","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"85832_CR39","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/j.2051-5545.2008.tb00154.x","volume":"7","author":"A \u00dc\u00e7ok","year":"2008","unstructured":"\u00dc\u00e7ok, A. & Gaebel, W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry 7 (1), 58 (2008).","journal-title":"World Psychiatry"},{"issue":"1","key":"85832_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/sj.mp.4002066","volume":"13","author":"H Nasrallah","year":"2008","unstructured":"Nasrallah, H. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol. Psychiatry 13 (1), 27\u201335 (2008).","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"85832_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/01.jcp.0000085413.08426.41","volume":"23","author":"CR Dolder","year":"2003","unstructured":"Dolder, C. R. et al. Interventions to improve antipsychotic medication adherence: review of recent literature. J. Clin. Psychopharmacol. 23 (4), 389\u2013399 (2003).","journal-title":"J. Clin. Psychopharmacol."},{"issue":"9881","key":"85832_CR42","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1016\/S0140-6736(13)60951-4","volume":"381","author":"K Morris","year":"2013","unstructured":"Morris, K. Revising the declaration of Helsinki. Lancet 381 (9881), 1889\u20131890 (2013).","journal-title":"Lancet"},{"key":"85832_CR43","doi-asserted-by":"crossref","unstructured":"Guy, W. ECDEU Assessment Manual for Psychopharmacology (US Department of Health, Education, and Welfare, Public Health Service, 1976).","DOI":"10.1037\/e591322011-001"},{"key":"85832_CR44","doi-asserted-by":"crossref","unstructured":"Kumari, S. et al. An Assessment of five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) commonly used symptoms rating scales in schizophrenia and comparison to newer scales (CAINS, BNSS). J. Addict. Res. Therapy 8(3), 324 (2017).","DOI":"10.4172\/2155-6105.1000324"},{"key":"85832_CR45","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1034\/j.1600-0447.107.s416.5.x","volume":"107","author":"JM Haro","year":"2003","unstructured":"Haro, J. M. et al. The clinical global impression\u2013schizophrenia scale: A simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatry. Scand. 107, 16\u201323 (2003).","journal-title":"Acta Psychiatry. Scand."},{"key":"85832_CR46","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1590\/S1516-44462007000300010","volume":"29","author":"MS Lima","year":"2007","unstructured":"Lima, M. S. et al. The Portuguese version of the clinical global impression-schizophrenia scale: Validation study. Brazilian J. Psychiatry 29, 246\u2013249 (2007).","journal-title":"Brazilian J. Psychiatry"},{"issue":"8","key":"85832_CR47","doi-asserted-by":"publisher","first-page":"e0201225","DOI":"10.1371\/journal.pone.0201225","volume":"13","author":"Y AlRuthia","year":"2018","unstructured":"AlRuthia, Y. et al. Translation and cultural adaptation of Glasgow antipsychotic side-effects scale (GASS) in Arabic. PloS One 13 (8), e0201225 (2018).","journal-title":"PloS One"},{"issue":"2","key":"85832_CR48","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/08039488.2017.1400097","volume":"72","author":"D Ignjatovi\u0107 Risti\u0107","year":"2018","unstructured":"Ignjatovi\u0107 Risti\u0107, D. et al. The Glasgow antipsychotic side-effects scale for clozapine in inpatients and outpatients with schizophrenia or schizoaffective disorder. Nord. J. Psychiatry 72 (2), 124\u2013129 (2018).","journal-title":"Nord. J. Psychiatry"},{"issue":"1","key":"85832_CR49","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1136\/emj.20.1.54","volume":"20","author":"C Mann","year":"2003","unstructured":"Mann, C. Observational research methods. Research design II: Cohort, cross sectional, and case-control studies. Emerg. Med. J. 20 (1), 54\u201360 (2003).","journal-title":"Emerg. Med. J."},{"issue":"10","key":"85832_CR50","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/sim.6058","volume":"33","author":"JM Franklin","year":"2014","unstructured":"Franklin, J. M. et al. Metrics for covariate balance in cohort studies of causal effects. Stat. Med. 33 (10), 1685\u20131699 (2014).","journal-title":"Stat. Med."},{"key":"85832_CR51","doi-asserted-by":"crossref","unstructured":"Behman, R., Bubis, L. & Karanicolas, P. Prospective and retrospective cohort studies. in Evidence-Based Surgery: A Guide to Understanding and Interpreting the Surgical Literature 159\u2013170 (2019).","DOI":"10.1007\/978-3-030-05120-4_16"},{"key":"85832_CR52","doi-asserted-by":"crossref","unstructured":"Sedgwick, P. Retrospective cohort studies: Advantages and disadvantages. Bmj 348, g1072 (2014).","DOI":"10.1136\/bmj.g1072"},{"issue":"1","key":"85832_CR53","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.chest.2020.03.014","volume":"158","author":"X Wang","year":"2020","unstructured":"Wang, X. & Kattan, M. W. Cohort studies: Design, analysis, and reporting. Chest 158 (1), S72\u2013S78 (2020).","journal-title":"Chest"},{"issue":"7561","key":"85832_CR54","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1136\/bmj.38881.382755.2F","volume":"333","author":"J Tiihonen","year":"2006","unstructured":"Tiihonen, J. et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. Bmj 333 (7561), 224 (2006).","journal-title":"Bmj"},{"key":"85832_CR55","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","volume":"37","author":"JT Callaghan","year":"1999","unstructured":"Callaghan, J. T. et al. Olanzapine: Pharmacokinetic and pharmacodynamic profile. Clin. Pharmacokinet. 37, 177\u2013193 (1999).","journal-title":"Clin. Pharmacokinet."},{"issue":"10","key":"85832_CR56","first-page":"13","volume":"58","author":"CM Beasley Jr","year":"1997","unstructured":"Beasley, C. M. Jr, Tollefson, G. D. & Tran, P. V. Safety of olanzapine. J. Clin. Psychiatry 58 (10), 13\u201317 (1997).","journal-title":"J. Clin. Psychiatry"},{"key":"85832_CR57","unstructured":"Thomas, K. & Saadabadi, A. Olanzapine (2018)."},{"issue":"7273","key":"85832_CR58","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","volume":"321","author":"J Geddes","year":"2000","unstructured":"Geddes, J. et al. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. Bmj 321 (7273), 1371\u20131376 (2000).","journal-title":"Bmj"},{"key":"85832_CR59","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s002130100711","volume":"155","author":"K Wahlbeck","year":"2001","unstructured":"Wahlbeck, K. et al. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology 155, 230\u2013233 (2001).","journal-title":"Psychopharmacology"},{"key":"85832_CR60","doi-asserted-by":"crossref","unstructured":"Leucht, S. et al. New generation antipsychotics versus low potency conventional antipsychotics: A systematic review and meta-analysis, vol 361, 1581 (2003).","DOI":"10.1016\/S0140-6736(03)13306-5"},{"issue":"4","key":"85832_CR61","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0006-3223(98)00291-1","volume":"45","author":"A Breier","year":"1999","unstructured":"Breier, A. & Hamilton, S. H. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol. Psychiatry 45 (4), 403\u2013411 (1999).","journal-title":"Biol. Psychiatry"},{"key":"85832_CR62","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2165\/00003495-199753020-00007","volume":"53","author":"B Fulton","year":"1997","unstructured":"Fulton, B. & Goa, K. L. Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53, 281\u2013298 (1997).","journal-title":"Drugs"},{"key":"85832_CR63","doi-asserted-by":"crossref","unstructured":"Citrome, L. et al. A commentary on the efficacy of olanzapine for the treatment of schizophrenia: The past, present, and future. Neuropsychiatric Dis. Treatm., 15, 2559\u20132569 (2019).","DOI":"10.2147\/NDT.S209284"},{"issue":"4","key":"85832_CR64","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","volume":"163","author":"TS Stroup","year":"2006","unstructured":"Stroup, T. S. et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am. J. Psychiatry 163 (4), 611\u2013622 (2006).","journal-title":"Am. J. Psychiatry"},{"issue":"9831","key":"85832_CR65","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","volume":"379","author":"S Leucht","year":"2012","unstructured":"Leucht, S. et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. Lancet 379 (9831), 2063\u20132071 (2012).","journal-title":"Lancet"},{"key":"85832_CR66","doi-asserted-by":"crossref","unstructured":"Pich, E. M., Vargas, G. & Domenici, E. Biomarkers for antipsychotic therapies. Handbook of Experimental Pharmacology. 212, 339\u2013360 (2012).","DOI":"10.1007\/978-3-642-25761-2_13"},{"issue":"8","key":"85832_CR67","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1176\/appi.ajp.160.8.1396","volume":"160","author":"JA Lieberman","year":"2003","unstructured":"Lieberman, J. A. et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol. Am. J. Psychiatry 160 (8), 1396\u20131404 (2003).","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"85832_CR68","doi-asserted-by":"publisher","first-page":"424","DOI":"10.2174\/1570159X21666221118164612","volume":"21","author":"Y Tang","year":"2023","unstructured":"Tang, Y. et al. Early efficacy of antipsychotic medications at week 2 predicts subsequent responses at Week 6 in a large-scale randomized controlled trial. Curr. Neuropharmacol. 21 (2), 424 (2023).","journal-title":"Curr. Neuropharmacol."},{"issue":"7","key":"85832_CR69","first-page":"227","volume":"75","author":"M Iyo","year":"2021","unstructured":"Iyo, M. et al. Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6-week, randomized, double\u2010blind, placebo\u2010controlled study. J. Neuropsychiatry Clin. Neurosci. 75 (7), 227\u2013235 (2021).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"issue":"1","key":"85832_CR70","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.eurpsy.2011.02.005","volume":"27","author":"E Barkhof","year":"2012","unstructured":"Barkhof, E. et al. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia: A review of the past decade. Eur. Psychiatry 27 (1), 9\u201318 (2012).","journal-title":"Eur. Psychiatry"},{"key":"85832_CR71","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.1016\/j.euroneuro.2007.02.003","volume":"17","author":"P Thomas","year":"2007","unstructured":"Thomas, P. The stable patient with schizophrenia: From antipsychotic effectiveness to adherence. Eur. Neuropsychopharmacol. 17, S115\u2013S122 (2007).","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1\u20132","key":"85832_CR72","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.psychres.2014.11.002","volume":"225","author":"KV Sendt","year":"2015","unstructured":"Sendt, K. V., Tracy, D. K. & Bhattacharyya, S. A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res. 225 (1\u20132), 14\u201330 (2015).","journal-title":"Psychiatry Res."},{"issue":"4","key":"85832_CR73","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/JCP.0000000000000523","volume":"36","author":"S Garc\u00eda","year":"2016","unstructured":"Garc\u00eda, S. et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: A systematic review. J. Clin. Psychopharmacol. 36 (4), 355\u2013371 (2016).","journal-title":"J. Clin. Psychopharmacol."},{"issue":"10","key":"85832_CR74","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.4088\/JCP.v67n1008","volume":"67","author":"M Valenstein","year":"2006","unstructured":"Valenstein, M. et al. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: A retrospective review. J. Clin. Psychiatry 67 (10), 1542\u20131550 (2006).","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"85832_CR75","first-page":"21","volume":"59","author":"SR Marder","year":"1998","unstructured":"Marder, S. R. Facilitating compliance with antipsychotic medication. J. Clin. Psychiatry 59 (3), 21\u201325 (1998).","journal-title":"J. Clin. Psychiatry"},{"key":"85832_CR76","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/00019053-200018020-00002","volume":"18","author":"E Lindstr\u00f6m","year":"2000","unstructured":"Lindstr\u00f6m, E. & Bingefors, K. Patient compliance with drug therapy in schizophrenia: Economic and clinical issues. Pharmacoeconomics 18, 105\u2013124 (2000).","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"85832_CR77","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4088\/JCP.v65n0311","volume":"65","author":"E Diaz","year":"2004","unstructured":"Diaz, E. et al. Adherence to conventional and atypical antipsychotics after hospital discharge. J. Clin. Psychiatry 65 (3), 354\u2013360 (2004).","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"85832_CR78","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2174\/157488406775268255","volume":"1","author":"PS Masand","year":"2006","unstructured":"Masand, P. S. & Narasimhan, M. Improving adherence to antipsychotic pharmacotherapy. Curr. Clin. Pharmacol. 1 (1), 47\u201356 (2006).","journal-title":"Curr. Clin. Pharmacol."},{"issue":"4","key":"85832_CR79","doi-asserted-by":"publisher","first-page":"147","DOI":"10.4088\/PCC.08r00612","volume":"11","author":"PS Masand","year":"2009","unstructured":"Masand, P. S. et al. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: A review. Prim. care Companion J. Clin. Psychiatry 11 (4), 147 (2009).","journal-title":"Prim. care Companion J. Clin. Psychiatry"},{"issue":"3","key":"85832_CR80","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/schbul\/21.3.419","volume":"21","author":"PJ Weiden","year":"1995","unstructured":"Weiden, P. J. & Olfson, M. Cost of relapse in schizophrenia. Schizophr. Bull. 21 (3), 419\u2013429 (1995).","journal-title":"Schizophr. Bull."},{"key":"85832_CR81","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.psychres.2017.06.069","volume":"256","author":"M Harrow","year":"2017","unstructured":"Harrow, M. et al. A 20-year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia. Psychiatry Res. 256, 267\u2013274 (2017).","journal-title":"Psychiatry Res."},{"issue":"6","key":"85832_CR82","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1177\/0004867413476755","volume":"47","author":"E Killackey","year":"2013","unstructured":"Killackey, E. & Allott, K. Utilising individual placement and support to address unemployment and low education rates among individuals with psychotic disorders. Austr. New. Z. J. Psychiatry. 47 (6), 521\u2013523 (2013).","journal-title":"Austr. New. Z. J. Psychiatry"},{"key":"85832_CR83","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1600-0447.2007.01083.x","volume":"116","author":"E Lindstr\u00f6m","year":"2007","unstructured":"Lindstr\u00f6m, E., Eberhard, J. & Levander, S. Five-year follow\u2010up during antipsychotic treatment: Efficacy, safety, functional and social outcome. Acta Psychiatry. Scand. 116, 5\u201316 (2007).","journal-title":"Acta Psychiatry. Scand."},{"issue":"4","key":"85832_CR84","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/schbul\/22.4.659","volume":"22","author":"RL Hayes","year":"1996","unstructured":"Hayes, R. L. & Halford, W. K. Time use of unemployed and employed single male schizophrenia subjects. Schizophr. Bull. 22 (4), 659\u2013669 (1996).","journal-title":"Schizophr. Bull."},{"issue":"1","key":"85832_CR85","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1186\/s12888-022-04022-x","volume":"22","author":"D Lin","year":"2022","unstructured":"Lin, D. et al. Unemployment, homelessness, and other societal outcomes in patients with schizophrenia: A real-world retrospective cohort study of the United States Veterans Health Administration database: Societal burden of schizophrenia among US veterans. BMC Psychiatry 22 (1), 458 (2022).","journal-title":"BMC Psychiatry"},{"key":"85832_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2191-1991-2-8","volume":"2","author":"AJ Garc\u00eda-Ruiz","year":"2012","unstructured":"Garc\u00eda-Ruiz, A. J. et al. Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses. Health Econ. Rev. 2, 1\u201312 (2012).","journal-title":"Health Econ. Rev."},{"key":"85832_CR87","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40258-015-0176-3","volume":"13","author":"SJ Lubinga","year":"2015","unstructured":"Lubinga, S. J. et al. A cost-effectiveness analysis of antipsychotics for treatment of schizophrenia in Uganda. Appl. Health. Econ. Health. Policy 13, 493\u2013506 (2015).","journal-title":"Appl. Health. Econ. Health. Policy"},{"issue":"1","key":"85832_CR88","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1749-6632.2001.tb05797.x","volume":"932","author":"HY Meltzer","year":"2001","unstructured":"Meltzer, H. Y. Treatment of suicidality in schizophrenia. Ann. N. Y. Acad. Sci. 932 (1), 44\u201360 (2001).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"85832_CR89","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2165\/11586450-000000000-00000","volume":"25","author":"J Kasckow","year":"2011","unstructured":"Kasckow, J., Felmet, K. & Zisook, S. Managing suicide risk in patients with schizophrenia. CNS Drugs 25, 129\u2013143 (2011).","journal-title":"CNS Drugs"},{"issue":"10","key":"85832_CR90","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1176\/ajp.156.10.1590","volume":"156","author":"ED Radomsky","year":"1999","unstructured":"Radomsky, E. D. et al. Suicidal behavior in patients with schizophrenia and other psychotic disorders. Am. J. Psychiatry 156 (10), 1590\u20131595 (1999).","journal-title":"Am. J. Psychiatry"},{"issue":"7","key":"85832_CR91","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3390\/medicina55070361","volume":"55","author":"L Sher","year":"2019","unstructured":"Sher, L. & Kahn, R. S. Suicide in schizophrenia: An educational overview. Medicina 55 (7), 361 (2019).","journal-title":"Medicina"},{"issue":"1\u20133","key":"85832_CR92","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.schres.2016.08.009","volume":"178","author":"D Verma","year":"2016","unstructured":"Verma, D. et al. Lifetime suicide intent, executive function and insight in schizophrenia and schizoaffective disorders. Schizophr. Res. 178 (1\u20133), 12\u201316 (2016).","journal-title":"Schizophr. Res."},{"issue":"6","key":"85832_CR93","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/acps.12332","volume":"130","author":"D Popovic","year":"2014","unstructured":"Popovic, D. et al. Risk factors for suicide in schizophrenia: Systematic review and clinical recommendations. Acta Psychiatry. Scand. 130 (6), 418\u2013426 (2014).","journal-title":"Acta Psychiatry. Scand."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85832-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85832-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85832-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T18:16:11Z","timestamp":1738952171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85832-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["85832"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-85832-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4663"}}